Updated Recommendations From the 2024 International Antiviral Society-USA Panel

The IAS-USA Antiretroviral Panel has updated its recommendations following the US FDA’s approval of lenacapavir for pre-exposure prophylaxis (PrEP) and new data on the use of tenofovir alafenamide/emtricitabine among cisgendered gendered women.

The updated recommendations can be found through the button below.